Ipamorelin is a pentapeptide GH secretagogue that acts on the ghrelin receptor (GHS-R1a) to stimulate growth hormone release from the anterior pituitary. It was developed as a selective alternative to earlier GHRPs like GHRP-2 and GHRP-6, and has been widely studied for its relatively clean receptor selectivity profile — stimulating GH release with less impact on cortisol and prolactin levels in pre-clinical models.

Research on Ipamorelin has examined its dose-response relationship in GH secretion models, its interaction with endogenous GHRH signaling, and how ghrelin receptor agonism influences pituitary somatotroph activity. Its selectivity has made it a useful pharmacological tool for researchers who need to isolate GH pathway effects without confounding effects on the HPA axis.

Studies have also explored Ipamorelin in the context of GH pulse timing and amplitude, particularly in models where researchers are characterizing the kinetics of pulsatile GH secretion and how different GHRPs compare. It's commonly used as a reference GHRP in comparative secretagogue research.

myPEPT supplies Ipamorelin at ≥99% verified purity with a Certificate of Analysis from independent lab testing. It is shipped lyophilized across the EU in research-grade packaging.

What researchers should know: Ipamorelin is a research peptide supplied for laboratory use only. It is not approved for human use as a therapeutic compound. Always follow your institution's compound handling guidelines and applicable local regulations when working with GH-related research peptides.